Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $46M | $43.3M | $31.4M | $11.6M | $620K | |
| Gross Profit | $41.4M | $39.6M | $28.4M | $10.8M | -$104K | |
| Operating Income | -$75.1M | -$145.9M | -$243.4M | -$45.2M | -$70.3M | |
| EBITDA | -$74.6M | -$144.3M | -$241.1M | -$44.8M | -$69.6M | |
| Diluted EPS | -$1.84 | -$2.31 | -$3.16 | -$0.64 | -$0.81 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $237.7M | $172.8M | $344.8M | $383.3M | $328.7M | |
| Total Assets | $263.4M | $180.4M | $355.2M | $418.5M | $364M | |
| Current Liabilities | $23.7M | $34.5M | $63.3M | $49M | $37M | |
| Total Liabilities | $79M | $84M | $88.9M | $82M | $57.9M | |
| Total Equity | $184.4M | $96.4M | $266.3M | $336.5M | $306.1M | |
| Total Debt | $38.6M | $35.3M | $4.9M | $21.9M | $20.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.9M | -$126.2M | -$240.1M | -$35.8M | -$65M | |
| Cash From Investing | -$3.3M | -$219.4M | $68.6M | -$96M | -$74.7M | |
| Cash From Financing | $187.1M | $164M | $173.6M | $151.7M | $167M | |
| Free Cash Flow | -$1.6M | -$130.3M | -$243.4M | -$36.2M | -$66M | |
EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
In the current month, EYPT has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EYPT average analyst price target in the past 3 months is $37.42.
According to analysts, the consensus estimate is that EyePoint Plc share price will rise to $37.42 per share over the next 12 months.
Analysts are divided on their view about EyePoint Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that EyePoint Plc is a Sell and believe this share price will drop from its current level to $20.00.
The price target for EyePoint Plc over the next 1-year time period is forecast to be $37.42 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for EyePoint Plc is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
You can purchase shares of EyePoint Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase EyePoint Plc shares.
EyePoint Plc was last trading at $13.21 per share. This represents the most recent stock quote for EyePoint Plc. Yesterday, EyePoint Plc closed at $14.92 per share.
In order to purchase EyePoint Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Since January 28th, software stocks in the United States have…
Over the last five days, shares of Instagram and Facebook…
Market Cap: $4.4T
P/E Ratio: 37x
Market Cap: $3.7T
P/E Ratio: 34x
Market Cap: $3.7T
P/E Ratio: 28x
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Nebius Group NV [NBIS] is up 0.87% over the past day.